Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial (vol 392, pg 31, 2018)

被引：0
|
作者：
Jaber, S.
Paugam, C.
Futier, E.
机构：
来源：
LANCET | 2018年 / 392卷 / 10163期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2440 / 2440
页数：1
相关论文
共 50 条
  • [21] Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018)
    Dummer, R.
    Ascierto, P. A.
    Gogas, H. J.
    [J]. LANCET ONCOLOGY, 2018, 19 (10): : E509 - E509
  • [22] Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
    Jin, Jie
    Wang, Jian-Xiang
    Chen, Fei-Fei
    Wu, De-Pei
    Hu, Jiong
    Zhou, Jian-Feng
    Hu, Jian-Da
    Wang, Jian-Min
    Li, Jian-Yong
    Huang, Xiao-Jun
    Ma, Jun
    Ji, Chun-Yan
    Xu, Xiao-Ping
    Yu, Kang
    Ren, Han-Yun
    Zhou, Yu-Hong
    Tong, Yin
    Lou, Yin-Jun
    Ni, Wan-Mao
    Tong, Hong-Yan
    Wang, Hua-Feng
    Mi, Ying-Chang
    Du, Xin
    Chen, Bao-An
    Shen, Yi
    Chen, Zhu
    Chen, Sai-Juan
    [J]. LANCET ONCOLOGY, 2013, 14 (07): : 599 - 608
  • [23] Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
    Chinula, Lameck
    Ziemba, Lauren
    Brummel, Sean
    McCarthy, Katie
    Coletti, Anne
    Krotje, Chelsea
    Johnston, Benjamin
    Knowles, Kevin
    Moyo, Sikhulile
    Stranix-Chibanda, Lynda
    Hoffman, Risa
    Sax, Paul E.
    Stringer, Jeffrey
    Chakhtoura, Nahida
    Jean-Philippe, Patrick
    Korutaro, Violet
    Cassim, Haseena
    Fairlie, Lee
    Masheto, Gaerolwe
    Boyce, Ceejay
    Frenkel, Lisa M.
    Amico, K. Rivet
    Purdue, Lynette
    Shapiro, Roger
    Mmbaga, Blandina Theophil
    Patel, Faeezah
    van Wyk, Jean
    Rooney, James F.
    Currier, Judith S.
    Lockman, Shahin
    [J]. LANCET HIV, 2023, 10 (06): : e363 - e374
  • [24] Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial (vol 19, pg 1192, 2018)
    Kim, Y. H.
    Bagot, M.
    Pinter-Brown, L.
    [J]. LANCET ONCOLOGY, 2018, 19 (11): : E581 - E581
  • [25] Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial (vol 393, pg 2416, 2019)
    Imel, E. A.
    Glorieux, F. H.
    Whyte, M. P.
    [J]. LANCET, 2019, 394 (10193): : 120 - 120
  • [26] Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial
    Neogi, Sutapa B.
    Devasenapathy, Niveditha
    Singh, Ranjana
    Bhushan, Himanshu
    Shah, Duru
    Divakar, Hema
    Zodpey, Sanjay
    Malik, Sunita
    Nanda, Smiti
    Mittal, Pratima
    Batra, Achla
    Chauhan, Meenakshi B.
    Yadav, Sunita
    Dongre, Harsha
    Saluja, Sumita
    Malhotra, Vani
    Gupta, Anjali
    Sangwan, Roopa
    Radhika, A. G.
    Singh, Alpana
    Bhaskaran, Sruti
    Kotru, Mrinalini
    Sikka, Meera
    Agarwal, Sonika
    Francis, Paul
    Mwingak, Kasonde
    Baswal, Dinesh
    [J]. LANCET GLOBAL HEALTH, 2019, 7 (12): : E1706 - E1716
  • [27] Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial (vol 18, pg 63, 2017)
    Freyer, D. R.
    Chen, L.
    Krailo, M. D.
    [J]. LANCET ONCOLOGY, 2017, 18 (06): : E301 - E301
  • [28] Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomised, open-label, blinded-endpoint, controlled trial in a health-care setting
    Breitenstein, Caterina
    Grewe, Tanja
    Floeel, Agnes
    Ziegler, Wolfram
    Springer, Luise
    Martus, Peter
    Huber, Walter
    Willmes, Klaus
    Ringelstein, E. Bernd
    Haeusler, Karl Georg
    Abel, Stefanie
    Glindemann, Ralf
    Domahs, Frank
    Regenbrecht, Frank
    Schlenck, Klaus-Juergen
    Thomas, Marion
    Obrig, Hellmuth
    de Langen, Ernst
    Rocker, Roman
    Wigbers, Franziska
    Ruehmkorf, Christina
    Hempen, Indra
    List, Jonathan
    [J]. LANCET, 2017, 389 (10078): : 1528 - 1538
  • [29] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial (vol 379, pg 633, 2012)
    Baselga, J.
    Bradbury, I
    Eidtmann, H.
    [J]. LANCET, 2012, 379 (9816): : 616 - 616
  • [30] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    Rittmeyer, Achim
    Barlesi, Fabrice
    Waterkamp, Daniel
    Park, Keunchil
    Ciardiello, Fortunato
    von Pawel, Joachim
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Kowalski, Dariusz M.
    Dols, Manuel Cobo
    Cortinovis, Diego L.
    Leach, Joseph
    Polikoff, Jonathan
    Barrios, Carlos
    Kabbinavar, Fairooz
    Frontera, Osvaldo Aren
    De Marinis, Filippo
    Turna, Hande
    Lee, Jong-Seok
    Ballinger, Marcus
    Kowanetz, Marcin
    He, Pei
    Chen, Daniel S.
    Sandler, Alan
    Gandara, David R.
    [J]. LANCET, 2017, 389 (10066): : 255 - 265
12345